IXP

Phase 1Completed

0 views this week 0 watching💤 Quiet

Interest: 29/100

Hype Score

Development Stage

✓

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Focal Segmental Glomerulosclerosis (FSGS)

Conditions

Focal Segmental Glomerulosclerosis (FSGS)

Trial Timeline

Aug 2, 2024 → Dec 20, 2024

NCT ID

NCT06529796

About IXP

IXP is a phase 1 stage product being developed by Vertex Pharmaceuticals for Focal Segmental Glomerulosclerosis (FSGS). The current trial status is completed. This product is registered under clinical trial identifier NCT06529796. Target conditions include Focal Segmental Glomerulosclerosis (FSGS).

What happened to similar drugs?

4 of 10 similar drugs in Focal Segmental Glomerulosclerosis (FSGS) were approved

Approved (4) Terminated (1) Active (6)

✅OnabotulinumtoxinA 145 UNT [Botox]AbbVieApproved

✅DapagliflozinAstraZenecaApproved

✅Gabapentin, Lamotrigine, Levetiracetam, Pregabalin, Oxcarbacepine, Tiagabine, Topiramate, ZonisamidePfizerApproved

✅Levetiracetam + Carbamazepine + LamotrigineUCBApproved

🔄Empasiprubart + IVIG (Intravenous Immunoglobulin)ArgenxPhase 3

🔄Gadoxetic Acid Disodium (Primovist, BAY86-4873)BayerPhase 3

🔄XEN1101 + PlaceboXenon PharmaceuticalsPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (2)

NCT ID	Phase	Status	Start	Completion	Indication
NCT06529796	Phase 1	Completed	Aug 2, 2024	Dec 20, 2024	Focal Segmental Glomerulosclerosis (FSGS)
NCT05865171	Phase 1	Completed	Jun 12, 2023	Jun 12, 2024	Renal Impairment

Competing Products

20 competing products in Focal Segmental Glomerulosclerosis (FSGS)

See all competitors

Product	Company	Stage	Hype Score
OnabotulinumtoxinA 145 UNT [Botox]	AbbVie	Approved	35
Dapagliflozin	AstraZeneca	Approved	43
Enfuvirtide + Tenofovir-Emtricitabine	Roche	Phase 2	35
CCX140-B	Amgen	Phase 2	27
PF-06730512	Pfizer	Phase 2	27
Gabapentin, Lamotrigine, Levetiracetam, Pregabalin, Oxcarbacepine, Tiagabine, Topiramate, Zonisamide	Pfizer	Approved	43
VX-147	Vertex Pharmaceuticals	Phase 2	35
VX-147	Vertex Pharmaceuticals	Phase 1	29
fresolimumab + fresolimumab + Placebo	Sanofi	Phase 2	35
GC1008 + GC1008 + GC1008 + GC1008	Sanofi	Phase 1	29
frexalimab + brivekimig + rilzabrutinib + placebo	Sanofi	Phase 2	42
Vivaglobin	CSL	Phase 2	35
UCB0942	UCB	Phase 2	27
Levetiracetam + Carbamazepine + Lamotrigine	UCB	Approved	43
Brivaracetam + Brivaracetam	UCB	Phase 2	35
Lacosamide	UCB	Phase 2	27
UCB0942 + UCB0942 + Placebo	UCB	Phase 2	35
Lacosamide	UCB	Pre-clinical	26
ARGX-117	Argenx	Phase 2	36
Empasiprubart + IVIG (Intravenous Immunoglobulin)	Argenx	Phase 3	44